Abstract:The Wnt/β-catenin signaling pathway plays extensive roles in cancer initiation, proliferation, and development, and has been implicated in the regulation of stem cells in the intestinal crypt, widely accepted as responsible for colorectal cancer (CRC) origination. This pathway has been a target of interest for many years for chemotherapeutic development of CRC due to its implication in most cases. Previously, a series of naphthoquinone analogs have been identified to inhibit the Wnt/β-catenin. It was postulated that these compounds exhibit their inhibitory activity via binding to β-catenin at the β-catenin/TCF4 interaction interface. In this study, we aimed to further define the critical pharmacophore for these compounds and verify their mechanisms of action for their abilities to inhibit the Wnt/β-catenin signaling pathway. Interestingly, our data suggested two of the compounds, compounds 3 and 6, may potently inhibit the Wnt/β-catenin signaling pathway via inhibition of the TCF4/DNA interaction, a novel finding compared to previous studies on these compounds. Our computational studies suggested that the compounds bound within the DNA binding HMG-box domain of TCF4 to elicit their inhibitory action. These compounds inhibited Wnt signaling in a dose dependent manner, suppressed Wnt direct target genes and demonstrated unforeseen degradation of the TCF4 protein. Thus, this study revealed a potentially novel mechanism of action of the chloro-naphthoquinone as possibly a multi-targeting scaffold, which warrants further investigation in future drug discovery on the 'undruggable" TCF proteins and an aberrantly activated Wnt/β-catenin signaling pathway.

Development of Structure-Based Pharmacophore to Target the Β-Catenin-tcf Protein–protein Interaction

Discovery of small molecule modulators targeting β-catenin interactions using molecular docking and molecular dynamics strategy

Molecular docking-aided identification of small molecule inhibitors targeting β-catenin-TCF4 interaction

Drug discovery efforts toward inhibitors of canonical Wnt/13-catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010-2020)

Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.

Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners

Direct Targeting of -Catenin in the Wnt Signaling Pathway: Current Progress and Perspectives

Is β-Catenin a Druggable Target for Cancer Therapy?

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety.

Discovery of Novel Inhibitor for WNT/-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening

Structure‐Based Design of Bicyclic Helical Peptides That Target the Oncogene β‐Catenin

Drug discovery efforts toward inhibitors of canonical Wnt/β-catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010–2020)

Targeting the β-catenin signaling for cancer therapy

Decoding Β-Catenin Associated Protein-Protein Interactions: Emerging Cancer Therapeutic Opportunities

Structure-Based Optimization of Small-Molecule Inhibitors for the Β-Catenin/b-cell Lymphoma 9 Protein-Protein Interaction.

Discovery of 2-(3-(3-carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives As Novel Small-Molecule Inhibitors of the Β-Catenin/b-cell Lymphoma 9 Protein–Protein Interaction

Discovery Of An Orally Bioavailable Small-Molecule Inhibitor For The Beta-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction

Rational Design of Small-Molecule Inhibitors for Β-Catenin/t-cell Factor Protein–Protein Interactions by Bioisostere Replacement

Targeting Wnt/β-Catenin Pathway for Drug Therapy

Exploration of naphthoquinone analogs in targeting the TCF-DNA interaction to inhibit the Wnt/β-catenin signaling pathway